Kurzfassung

A Phase III Randomized, Double-blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer